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Abstract
CCHCR1 (Coiled-Coil a-Helical Rod protein 1), within the major psoriasis susceptibility locus PSORS1, is a plausible candidate
gene with the psoriasis associated risk allele CCHCR1*WWCC. Although its expression pattern in psoriatic skin differs from
healthy skin and its overexpression influences cell proliferation in transgenic mice, its role as a psoriasis effector gene has
remained unsettled. The 59-region of the gene contains a SNP (rs3130453) that controls a 59-extended open reading frame
and thus the translation of alternative isoforms. We have now compared the function of two CCHCR1 isoforms: the novel
longer isoform 1 and the previously studied isoform 3. In samples of Finnish and Swedish families, the allele generating only
isoform 3 shows association with psoriasis (P,1027). Both isoforms localize at the centrosome, a cell organelle playing a role
in cell division. In stably transfected cells the isoform 3 affects cell proliferation and with the CCHCR1*WWCC allele, also
apoptosis. Furthermore, cells overexpressing CCHCR1 show isoform- and haplotype-specific influences in the cell size and
shape and alterations in the organization and expression of the cytoskeletal proteins actin, vimentin, and cytokeratins. The
isoform 1 with the non-risk allele induces the expression of keratin 17, a hallmark for psoriasis; the silencing of CCHCR1
reduces its expression in HEK293 cells. CCHCR1 also regulates EGF-induced STAT3 activation in an isoform-specific manner:
the tyrosine phosphorylation of STAT3 is disturbed in isoform 3-transfected cells. The centrosomal localization of CCHCR1
provides a connection to the abnormal cell proliferation and offers a link to possible cellular pathways altered in psoriasis.
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Introduction
Psoriasis is a chronic skin disease that affects 2–3% of people
with European descent and is less common in other populations
such as in Asia and Africa [1]. The most important chromosomal
region for psoriasis predisposition is PSORS1 in the Human
Leukocyte Antigen region (HLA, 6p21.3) where also CCHCR1
(Coiled-Coil a-Helical Rod protein 1), by position a plausible
psoriasis candidate gene, is located [2,3]. Even though CCHCR1
resides in the chromosomal region showing the strongest
associations in genome-wide association studies [4], its role and
function in the pathogenesis of psoriasis is still unclear. The
CCHCR1 gene is highly polymorphic and has the allele
CCHCR1*WWCC associated with psoriasis in several populations
[2,3,5]. ‘‘WWCC’’ stands for the amino acids in the psoriasis risk
haplotype, whereas in the non-risk haplotype the corresponding
amino acids are RRGS. The CCHCR1 protein does not belong to
any known protein family but is predicted to be a rod-like protein,
with an alpha-helical coiled coil structure. The expression of
CCHCR1 is different in psoriatic lesions when compared with
healthy skin or other hyperproliferative skin disorders [6]. We and
others have demonstrated that CCHCR1 regulates the synthesis of
steroids from cholesterol in mitochondria by interacting with the
steroidogenic activator protein StAR [7,8]. Interestingly, a recent
gene expression analysis revealed evidence for decreased lipid
biosynthesis in uninvolved psoriatic skin, supporting the role of
altered lipid metabolism in the pathogenesis of psoriasis [9]. Our
recent findings showed that overexpression of CCHCR1 affects
keratinocyte proliferation in transgenic mice. The most evident
effect was observable after wounding and treatment with 12-O-
tetradecanoyl-13-acetate (TPA); the number of proliferating
keratinocytes was decreased and wound healing delayed in mice
with the CCHCR1*WWCC risk allele [10]. Furthermore, the
expression of several genes relevant in psoriasis pathogenesis were
altered, these including cytokeratins 6, 16, and, 17, and genes of
the epidermal differentiation complex region on the PSORS4 locus
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(1q21), such as S100 calcium binding protein A1 (S100A) and
small proline-rich protein (SPRR) [11].
As psoriasis and cancer share some characteristics, such as
accelerated cell proliferation, angiogenesis, and inflammation, we
have previously studied the expression of CCHCR1 in the non-
melanoma skin cancers squamous cell carcinoma (SCC) and basal
cell carcinoma (BCC) [12]. In these tumors, unlike in psoriasis,
CCHCR1 is expressed especially in proliferating cells (Ki67
positive). Furthermore, CCHCR1 mRNA expression is upregulated
in SCC cultures when compared to normal keratinocytes.
Recently, a similar increase in CCHCR1 expression was observed
in neoplastic cervical H-SIL samples (high-grade squamous
intraepithelial lesions) [13]. Interestingly, the strongest CCHCR1
expression in SCCs and BCCs is observed in areas positive for
epidermal growth factor receptor (EGFR). This is in agreement
with the finding that EGF induces CCHCR1 expression in
keratinocytes [8]. EGFR and its related receptors are well known
markers in several solid tumors and their expression and signaling
are implicated in psoriasis pathogenesis as well [14,15,16]. The
persistent stimulation of EGFR was suggested to result in the
constitutive activation of signal transducer and activator of
transcription signal protein 3 (STAT3), having pathogenic effects
in skin via alteration of biological processes, such as proliferation,
differentiation, and apoptosis of keratinocytes [17,18,19,20].
The centrosome determines the organization of the spindle
poles during mitosis, therefore having a crucial function in cell
division [21,22]. It also plays a role in the organization of the
microtubules and through its influence on the cytoskeleton it
regulates cell shape, motility, and polarity. The centrosome
consists of a pair of centrioles that are surrounded by a dense
fibrillar network of proteins, called pericentriolar material (PCM).
It comprises hundreds of proteins with many different functions,
with c-tubulin as a constitutive component. Defects in genes
encoding centrosomal proteins, such as mitotic checkpoint genes,
can cause abnormalities that are identifiable in most human
cancer cells. For instance Aurora kinase A, a protein needed for
the timely entry into mitosis, maturation of centrosomes, and
assembly of bipolar spindles, is implicated in the development of
epithelial cancers, such as SCC [23]. Also b-catenin, a molecule
involved in Wnt pathway and cell-cell adhesion, was recently
detected at the centrosome, where its phosphorylation regulates
centrosome splitting and microtubule re-growth [24,25,26].
Alterations in b-catenin expression and Wnt signaling are
observed in lesional psoriatic skin and also in cancers [27,28].
We have cloned a novel isoform 1 of CCHCR1 where the N-
terminal domain is 89 amino acids longer than in the previously
studied isoform 3. The formation of the isoforms is dependent on a
SNP (rs3130453) that with alleles G and A results in either
tryptophan (allele Iso1) or a stop codon (allele Iso3), respectively.
Here we studied if either of the alleles Iso1 or Iso3 associates with
psoriasis in family samples and whether the extended N-terminus
of isoform 1 affects the localization and function of CCHCR1. By
generating stable cell lines expressing either of the isoforms 1 and 3
with the non-risk (RRGS) or the risk haplotype (WWCC), we show
that CCHCR1 has isoform- and allele specific effects in the cell.
We hypothesize that an aberrant function of CCHCR1 might lead
to abnormal keratinocyte growth, which is a key feature of the
psoriatic epidermis.
Results
Cloning and expression of a novel CCHCR1 isoform 1
A database survey suggested a putative longer isoform of
CCHCR1. Based on NCBI’s GenBank database, CCHCR1 has
alternative transcripts 1 and 3 (NM_001105564.1, NM_019052.3,
respectively) resulting from two alternative transcription start sites
(Fig. 1A) [7]. The previously studied CCHCR1 (HCR) cDNA
[3,11] corresponds to the transcript 3 starting with exon 1a and
encoding for the shorter protein (isoform 3), whereas the transcript
1 starting with exon 1b is additionally able to encode for a longer
protein (isoform 1) depending on a SNP (rs3130453) in exon 2.
The SNP (G/A) creates either a codon for tryptophan (G) or a stop
codon (A). The stop codon (allele Iso3) results in the shorter
isoform whereas the codon for tryptophan (allele Iso1) enables the
usage of an earlier translation start site in exon 1b, thus leading to
a protein with 89 additional amino acids in its N-terminal domain.
This N-terminal part shows no homology to any known proteins
or protein motifs. To confirm the existence of both variants in vivo,
we studied the mRNA expression of transcripts 1 and 3 of
CCHCR1 in various human tissues and cell lines using RT-PCR.
Both transcripts are detectable in all tissues and cells studied and
do not show any major differences in their expression (Table S1).
To study the function of CCHCR1 we cloned both variants into
the pDsRed-tagged vector and generated HEK293 cell lines
overexpressing either the isoform 1 or 3 with the risk
(CCHCR1*WWCC) or the non-risk (CCHCR1*RRGS) haplotype
(Fig. S1A and B). Lines are called: Iso1Risk, Iso1Non-risk,
Iso3Risk, and Iso3Non-risk. We also established stable shRNA
cell lines using HEK293 cells in which CCHCR1 expression is
downregulated 50–60% (Fig. S1C). The HEK293 cells are
homozygous for the CCHCR1 non-risk and Iso1 alleles and are
therefore able to endogenously express also the isoform 1. A
construct with scrambled sequence was used to prepare a control
shRNA cell line.
The SNP creating isoform 3 associates with psoriasis
To study the possible connection between the CCHCR1
isoforms and psoriasis, we genotyped the SNP rs3130453 (G/A)
in 508 Finnish and Swedish psoriasis families (Table 1). The A
allele resulting in the translation of only CCHCR1 isoform 3 (Iso3
allele) shows preferential transmission from heterozygous parents
to affected offspring (P,1027). We also measured mRNA levels of
transcripts 1 and 3 in skin samples from Finnish patients by using
quantitative PCR (qPCR), but did not observe any differences in
their expression (P.0.05) between non-lesional and lesional skin
(data not shown). The mRNA amount of variant 1, however, is not
directly comparable to the isoform 1 protein expression as
transcript 1 is able to encode for the shorter protein isoform 3
as well. We also genotyped rs130076 (C/T), corresponding for the
second R/W amino acid change in CCHCR1*WWCC, from the
same family material. The risk allele *W showed association with
psoriasis (P,10213), as expected [2,3]. Haplotype analysis with
transmission disequilibrium test (TDT) showed undertransmission
of *Iso1Non-risk (P,1027) and the transmission of *Iso3Risk
(P,10216) to affected offspring, suggesting that the complete
psoriasis risk allele is CCHCR1*Iso3WWCC (Table 2). The two
markers are also in high linkage disequilibrium (LD) (Fig. 1B), as is
the whole HLA-region within PSORS1.
CCHCR1 is localized at the centrosome
In stable HEK293 cell lines, all of the Iso1Risk, Iso1Non-risk,
Iso3Risk, and Iso3Non-risk DsRed-tagged CCHCR1 constructs
localize at the centrosome, showing overlapping or adjacent
expression with the centrosomal marker c-tubulin (Fig. 1B).
CCHCR1 co-localizes with b-catenin and its phosphorylated form
at the centrosome as well (Fig. 1C). Our IEM studies with stable
HEK293 Iso1 cells reveal that CCHCR1 is present at the
pericentrosomal region at about 200–1000 nm distance apart
CCHCR1 Regulates Cytoskeletal Organization
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from the centrioles (Fig. S1D). The CCHCR1 protein is detectable
throughout the cell cycle (Fig. 2), partially overlapping with c-
tubulin. The localization is dynamic and fluctuates especially
during mitosis. Near the end of cytokinesis, when the dividing cells
are still connected, CCHCR1 is also detectable at the midbody
(Fig. 2). The co-localization with c-tubulin was confirmed also in
transiently transfected primary normal human epidermal kerati-
nocytes (NHEK) (Fig. S2A).
All four CCHCR1 isoforms are also visible as cytoplasmic
granules that do not co-localize with microtubule proteins a- and
b-tubulin. A high proportion (75%) of centrosomal proteins
contains coiled-coil regions in their structure, as CCHCR1; many
of them form cytoplasmic aggregates when overexpressed [29].
Closer microscopic examination of transiently transfected
HEK293, HaCaT and NHEK cells reveals that the Iso3Risk
construct forms larger granules in the cytoplasm (data not shown).
The IEM with transiently transfected COS-7 cells (Fig. S2C) and
HaCaT cells (data not shown) support the observation. Immuno-
fluorescent staining with vimentin antibody shows that CCHCR1
granules are not surrounded by a vimentin cage (Fig. S4B) that
forms around an aggresome, which is an organelle composed of
misfolded aggregated proteins and located adjacent to the
centrosome [30]. We also detected that especially in transiently
transfected primary keratinocytes (NHEK) the Iso3Risk shows
stronger perinuclear staining than the other constructs (Fig. S2B).
The staining is not recognized by a cis-golgi marker GM130 (data
not shown), which has a function as a regulator of centrosomes as
well. As demonstrated in stably transfected HEK293 (Fig. S2D),
GM130 surrounds the centrosomal CCHCR1. Otherwise all
constructs localize to the centrosome and form cytoplasmic
granules also in primary keratinocytes.
Immunofluorescent stainings show that also the endogenous
CCHCR1 protein localizes at the centrosome in HEK293 and
HaCaT cells (Fig. S3A and B). The expression level is extremely
low in both cell lines and in HaCaT cells the small size of
centrosomes makes it even more difficult to detect CCHCR1
protein. Unlike the DsRed-tagged CCHCR1 isoforms (tag in the
C-terminus), the endogenous protein stained with an antibody
against the N-terminal part of isoform 3 is detectable also at the
cell-cell borders (Fig. S1A). This suggests a plausible modification
or cleavage of the C-terminus, before the transportation of the
protein to the cell-cell border. The lower band of CCHCR1 in
Western Blot supports the observation and possibility of modifi-
cation (Fig. S1B). Interestingly, in skin samples the IEM reveals
labeling in the close proximity of cell membranes in association
with desmosomes both in psoriatic and healthy skin (data not
shown).
CCHCR1 affects cytoskeleton and has a dynamic
localization in the cell
The stable overexpression of CCHCR1 brings out morpholog-
ical alterations in HEK293 cells; isoforms 1 and 3 have opposite
effects on the cell size and shape (Fig. 3; Fig. S4). Iso1Non-risk-
expressing cells seem to be bigger in size and rounder in shape,
having larger area of cytoplasm than the Iso1Risk cells, whereas
both isoform 3-expressing cell lines are even smaller and have
more membrane protrusions. Also the size of cell nuclei in
interphase differs between isoform 1 and 3 cell lines (P,1026) (Fig.
S4C). Furthermore, nuclear aberrations such as multilobular
nuclei are detectable in the cell lines overexpressing CCHCR1,
especially in Iso1Non-risk cells (Fig. 3; Fig. S4A). As the
centrosome regulates the organization of microtubules and
therefore modulates the cytoskeleton, we studied the relationship
between CCHCR1 and the microtubulus network alongside
Figure 1. Alternative transcription of CCHCR1 into transcripts 1
and 3 and localization to the centrosome. (A) The numbers
represented above the schematic gene structure (not in scale) represent
the exons. Transcripts 1 and 3, starting with either exon 1a (transcript 3)
or 1b (transcript 1), result from alternative transcription start sites that
are featured more clearly in the magnification of the 59-region. The light
grey color represents the untranslated region and the darker grey
indicates the sequence for the additional 59-region in the isoform 1,
lacking from isoform 3. The red arrow in exon 2 indicates the SNP
(rs3130453) with alleles G and A creating either tryptophan or stop
codon, respectively. The former enables the usage of an earlier initiation
codon (ATG) in the reading frame. The black and grey arrows show the
positions of the WWCC haplotype SNPs in exons 4, 14, and 18. (B) The
SNP regulating the 59 open reading frame (rs3130453, *Iso1/Iso3) and
one of the *WWCC SNPs (rs130076, second W) are in high linkage
disequilibrium. (C) CCHCR1 localizes in the centrosomal area. Ds-Red-
tagged CCHCR1 (red) shows co-localization with the centrosomal
marker c-tubulin (green) in stably transfected HEK293 cells. All CCHCR1
isoforms localize at the centrosome, here shown Iso1Non-risk and
Iso3Risk. (D) CCHCR1 also co-localizes with the phosphorylated form of
b-catenin at the centrosome. DAPI stained nuclei are shown in blue.
Scale bars 10 mm.
doi:10.1371/journal.pone.0049920.g001
CCHCR1 Regulates Cytoskeletal Organization
PLOS ONE | www.plosone.org 3 November 2012 | Volume 7 | Issue 11 | e49920
cytoskeletal proteins actin, vimentin, and cytokeratins. We treated
the stable cells with nocodazole, an agent able to disrupt
microtubule structures. After the treatment, the number of
cytoplasmic CCHCR1 granules increases remarkably but also
the centrosomal localization is still observable, suggesting a partial
dependency of the CCHCR1 localization on microtubules (Fig.
S5C). The overexpression of different CCHCR1 isoforms does not
have major effects on the microtubulus network but the disruption
of the network with nocodazole, however, affected the attachment
and shape of the Iso3Risk cells by making them clump together
(data not shown).
We studied the effects of CCHCR1 expression on actin (Fig. 3;
all CCHCR1 cell lines shown in Fig. S5) and vimentin (Fig. S4)
intermediate filaments by immunofluorescence microscopy. The
actin cytoskeleton of isoform 1 overexpressing cells is similar to
vector control or wild type HEK293 cells. However, phalloidine
staining suggests altered actin cytoskeleton of isoform 3 cells (Fig. 3;
Fig. S5), which exhibit long filopodial projections with actin-rich
tips. The most obvious abnormality is observed after disruption of
the microtubulus network with nocodazole; after the treatment,
actin is also detectable as punctate staining in the cytoplasm. The
actin rich spheres resemble podosomal or invadopodial structures,
which are actin rich protrusions of the cell membrane [31]. Based
on immunofluorescent staining the CCHCR1 overexpressing cell
lines differ slightly also in vimentin organization and expression
but immunoblotting shows only minor differences in the protein
expression level between different CCHCR1 cell lines (Fig. S4B
and D). Disruption of the cytoskeleton with nocodazole, however,
lacks similar alterations in vimentin organization as in actin (data
not shown).
Our previous microarray results with transgenic mice suggest
that CCHCR1 might regulate the expression of cytokeratins [11].
Immunofluorescent staining of stable CCHCR1 cell lines with a
pan-cytokeratin antibody reveals decreased expression in Iso3Risk
cells (Fig. 4A, all CCHCR1 cell lines shown in Fig. S6). Similar
downregulation of cytokeratin expression in Iso3Risk line is
observable by immunoblotting (Fig. 4B). Western blotting reveals
also that the silencing of CCHCR1 in HEK293 cells results in an
overall reduction of cytokeratin expression (Fig. 4B).
Keratin 17 (KRT17) is implicated in the psoriasis pathogenesis
and its expression is altered in experiments with transgenic mice
overexpressing CCHCR1 [11,32]. Immunofluorescent staining of
KRT17 in stably transfected CCHCR1 cells reveals increased
expression in Iso1Non-risk cells, whereas the labeling in Iso1Risk
cells resembles the control cell line (Fig. 4A). In Iso3Non-risk and –
Risk cells only a few cells are positive for KRT17. The
immunofluorescent results agree well with the qPCR and western
blotting (Fig. 4B and C) data showing a significant induction of
KRT17 expression in the Iso1Non-risk cells. Furthermore, as
shown by immunoblotting and qPCR, the silencing of CCHCR1
downregulates KRT17 expression in HEK293 cells (Fig. 4B and
C).
CCHCR1 regulates EGF-induced STAT3 phosphorylation
We have recently shown that EGF stimulates CCHCR1
expression in HaCaT keratinocytes [8]. Here, we found that
besides inducing CCHCR1 expression the EGF also affects its
localization in stably transfected CCHCR1 cell lines (Fig. 5A).
After EGF treatment, CCHCR1 is still present at the centrosome
but its cytoplasmic localization changes. Furthermore, its expres-
sion increases remarkably both on RNA and protein level, shown
by qRT-PCR (Fig. 5B) and western blotting (Fig. S1A). All four
CCHCR1 isoforms respond similarly to EGF treatment, although
the expression level of Iso1Non-risk accelerates the most. We also
studied the effects of CCHCR1 isoforms on STAT3 activation by
western blotting using antibodies against tyrosine 705 or serine
727 phosphorylated STAT3 and lysine 685 acetylated STAT3.
We found that the isoform 1 overexpressing cells show slightly
stronger EGF-induced STAT3 tyrosine 705 phosphorylation than
the wild type HEK293 cells, whereas the STAT3 phosphorylation
is disturbed in isoform 3 cells (Fig. 5C). In addition, silencing of
CCHCR1 in HEK293 cells decreases the tyrosine 705 phosphor-
ylation (Fig. 5C). Overexpression or silencing of CCHCR1 affects
neither the expression level of STAT3 (Fig. 5) nor its serine 727
phosphorylation or lysine 685 acetylation (Fig. S7). The Iso1Non-
Table 1. Transmission equilibrium of *Iso3 (rs3130453) and one of the Risk-allele *WWCC (rs130076) SNPs as single markers in
psoriasis family samples of Finnish and Swedish origin.
SNP ID HWpval FamTrio MAF Alleles Overtransm T:U x2 P-value
rs3130453 0.3895 531 0.461 A:G A 285:168 30.219 3.86*1028
rs130076 0.5943 497 0.273 C:T T 229:91 59.512 1.22*10214
Abbreviations: MAF, minor allele trequency; SNP, single-nucleotide polymorphism; HWpval, Hardy-Weinberg equilibrium P-value; T, transmitted; U, untransmitted.
Significant P-values are shown in bold.
doi:10.1371/journal.pone.0049920.t001
Table 2. Transmission equilibrium of *Iso3 (rs3130453) and one of the Risk-allele *WWCC (rs130076) SNPs as haplotypes in
psoriasis family samples of Finnish and Swedish origin.
rs3130453 rs130076 Freq T:U x2 P-value Effect Description
G C 0.455 177.2:292.9 28.463 9.55*1028 Protective Iso1 RRGS
A T 0.274 266.6:104.3 71.032 3.51*10217 Risk Iso3 WWCC
A C 0.268 160.5:203.1 4.995 0.03 Neutral Iso3 RRGS
Abbreviations: SNP, single-nucleotide polymorphism; T, transmitted; U, untransmitted; Iso1, CCHCR1 isoform 1; Iso3, CCHCR1 isoform 3; RRGS, amino acids in non-risk
haplotype; WWCC, risk haplotype. Significant P-values are shown in bold.
doi:10.1371/journal.pone.0049920.t002
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risk cells and in some extent also Iso1Risk cells are able to induce
tyrosine 750 phosphorylation also in the absence of EGF
treatment.
Effects of CCHCR1 on cell proliferation and apoptosis
Nuclear aberrations in stable CCHCR1 cell lines suggest
abnormalities in the cell cycle control. Furthermore, isoform 3
cells differ from other cell lines at the growth rate. When the cell
number was determined with a fully automated cell counter
(Scepter, Millipore), after a culturing of 24 or 48 h, we found that
both isoform 3 overexpressing cell lines multiply faster (P,0.03
and P,0.07, respectively) than the Iso1Non-risk, wild type, or
vector control cells (Fig. 6A); after a growth period the increase in
the cell number is 40–60% higher in isoform 3 cells than in other
cell lines. The Iso1Non-risk cells show similar proliferation as wild
type and vector control cells, whereas the growth of Iso1Risk cells
resembles isoform 3-expressing cells. The CyQUANTH Cell
Proliferation assay (Invitrogen) did not reveal any statistically
significant differences but showed a high variation in measurement
values (data not shown). Differences in the size of nuclei may have
an effect on cell proliferation methods based on DNA staining,
such as the CyQUANTH system. The Iso1Non-risk-expressing
cells exhibit more multilobular cell nuclei that are able to bind
more CyQUANTH reagent than the other cells, especially isoform
3-expressing cells with smaller nuclei. To study the cell cycle, we
did FACS assays using propidium iodide staining of the DNA. The
cell cycle and progression from synchronized cell phase is
otherwise normal in all CCHCR1 cell lines (Fig. 6B), except in
Iso3Risk cells, where the population for apoptotic cells is
significantly higher (P,0.03). Synchronization of cells to the same
phase for cell cycle progression measurements was done with
0.3 mM nocodazole over night, after which the media was changed
and the cells harvested and fixed at specific time points. FACS
demonstrated that after the synchronization the population of
apoptotic cells is higher in Iso3Risk line than other cell lines; 30%
and 10–24%, respectively (Fig. 6B). The proliferation and cell
cycle of CCHCR1-silenced shRNA-cell lines was also measured
but lacked significant alterations when compared to control cell
lines (data not shown).
Figure 2. CCHCR1 protein is expressed throughout the cell
cycle but the localization is dynamic. Ds-Red-tagged CCHCR1 (red)
is stably expressed and the cells are stained with a-tubulin (a-TB, green)
antibodies for the detection of different points of the cell cycle
(metaphase, anaphase, telophase and cytokinesis). Near the end of
cytokinesis CCHCR1 is also detectable at the midbody region (arrow)
connecting the dividing cells. DAPI stained nuclei are shown in blue.
Scale bar 10 mm.
doi:10.1371/journal.pone.0049920.g002
Figure 3. Morphological and cytoskeletal alterations in CCHCR1-overexpressing stable cell lines. Actin staining (green) shows
differences in the cell morphology and cytoskeleton between cells expressing different CCHCR1 isoforms (red), here presented vector control,
Iso1Non-risk, and Iso3Risk cells. Isoform 1 and 3-expressing cells differ in cell size and shape; Iso1Non-risk cells are larger and rounder than Iso3Risk
and their cell nuclei are larger. Furthermore, of the CCHCR1 cell lines especially Iso1Non-risk cells show multilobulated cell nuclei (arrow). The isoform
3-expressing cells also exhibit more pseudopodia with actin rich tips, indicated by an arrowhead (upper panel). The most obvious change in actin
organization is observed in the Iso3Risk cells, after treatment with nocodazole (Noc); actin forms punctate staining resembling podosome-like
structures, indicated by an arrowhead (lower panel). DAPI stained nuclei are shown in blue. Scale bar 10 mm.
doi:10.1371/journal.pone.0049920.g003
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Discussion
The SNP creating the shorter CCHCR1 isoform associates
with psoriasis
The role of CCHCR1 as a susceptibility gene for psoriasis was
strengthened by genome-wide association studies where the SNPs
(rs130065, rs130076, rs3130453) from the coding region of
CCHCR1 showed strong association to psoriasis with P-values
varying between 1024 and 102150 [4,33,34,35]. Even though
HLA-Cw6, the main marker of PSORS1, remains equally or in
some studies more strongly associated with psoriasis, the mech-
anistic support for its role in this disease is missing. In the present
study, we cloned a novel longer CCHCR1 isoform 1 resulting
from a SNP (rs3130453) that changes a stop codon (*Iso3) into
tryptophan (*Iso1). The genetic analyses of psoriasis samples
suggests that the Iso3 allele creating the shorter isoform 3 associates
with psoriasis. Here we present that CCHCR1 localizes at the
centrosome and via affecting cytoskeletal organization and cell
proliferation, has haplotype specific functional consequences
relevant to the pathogenesis of psoriasis. Furthermore, our results
suggest that CCHCR1 might function in EGFR-STAT3 signaling,
previously implicated in psoriasis as well.
Cellular localization of CCHCR1 suggests a role in
processes related to microtubule organization
The expression level of endogenous CCHCR1 protein in cells is
extremely low, making its detection difficult. Thus, the exact
cellular localization of the CCHCR1 protein was unknown
hitherto. Here, we show with immunofluorescent staining and
DsRed-tagged protein constructs that both CCHCR1 isoforms 1
and 3 colocalize with c-tubulin at the centrosome. This is
supported by previous mass spectrometry studies, where
CCHCR1 was detected from extracted centrosomes [29,36].
Interestingly, we also demonstrated that CCHCR1 co-localizes at
the centrosome with b-catenin, a protein implicated in psoriasis
[28]. The centrosome has a crucial function in mitosis. Numerous
centrosomal proteins play a role in cytokinesis as well and are
identifiable at the intercellular bridge connecting the dividing cells.
Figure 4. CCHCR1 affects the expression of cytokeratins. (A, B) The overall expression of cytokeratins is reduced especially in the Iso3Risk
(Iso3R) overexpressing cells shown by (A) immunofluorescence staining (here presented vector control, Iso1Non-risk (Iso1N) and Iso3Risk (Iso3R) cells)
and (B) Western blotting with pan-cytokeratin (CK) antibody (green). The KRT17 expression is increased in the Iso1Non-risk cells (green). The up-
regulation of KRT17 is shown by (A) immunofluorescence (here presented vector control, Iso1Non-risk and Iso3Risk cells), (B) Western Blotting and
(C) qPCR. (B) EGF stimulates KRT17 expression in all the other, except the isoform 3-expressing cells. The silencing of CCHCR1 in HEK293 cells (shRNA)
downregulates KRT17 expression, shown by (B) Western blotting and (C) qPCR. (B) The expression of KRT17 under CCHCR1 silencing is not restored
by EGF stimulation. (B) Also the overall expression of cytokeratins is decreased in CCHCR1 silenced HEK293 cells demonstrated with pan-cytokeratin
(CK) antibody. Wt, non-transfected HEK293 cells; shRNA, HEK293 cells transfected with CCHCR1-shRNA construct; Scr, HEK293 transfected with the
scrambled sequence. Staining with an antibody for GAPDH was used to control sample loading on SDS-PAGEs. DAPI stained nuclei are shown in blue.
Scale bar 10 mm.
doi:10.1371/journal.pone.0049920.g004
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These including c-tubulin and b-catenin [24,37,38]. During
cytokinesis, CCHCR1 is also visible at the midbody between
daughter cells. In addition, the formation of multilobulated nuclei
Figure 5. CCHCR1 and EGFR-STAT3 signaling. The localization
and expression of CCHCR1 is altered after the stimulation of stable cell
lines with EGF as shown by (A) immunofluorescence staining and (B)
qPCR. (A) After EGF treatment cytoplasmic CCHCR1 (red) expression is
increased though some protein still co-localizes with c-tubulin (green),
thus remains at the centrosome. All isoforms respond similarly to EGF
(EGF+), in panel (A) Iso1Non-risk cells are shown. Also on RNA level (B),
when compared with non-treated cells (EGF-), all EGF-treated cell lines
show upregulation of CCHCR. Error bars represent SD. Following the
EGF treatment (100 ng/ml 18 h) in stably transfected cells, CCHCR1
overexpression has an isoform-specific effect on the STAT3 activation.
As shown by Western Blotting (C), the EGF-induced Tyrosine 705
phosphorylation of STAT3 is disturbed in both isoform 3-expressing cell
lines (Iso3Non-risk (Iso3N) and Iso3Risk (Iso3R)), whereas isoform 1 cells
(Iso1Non-risk (Iso1N) and Iso1Risk (Iso1R)) show similar STAT3
phosphorylation as wild type cells (wt). The Iso1Non-risk and in some
extent also Iso1Risk cells are able to induce tyrosine 750 phosphory-
lation without any EGF treatment. The silencing of CCHCR1 in HEK293
cells (shRNA) reduces tyrosine 750 phosphorylation when compared
with the control cell line transfected with the scrambled sequence (Scr)
or to wild type cells. Overexpression or silencing of CCHCR1 does not
affect the expression level of STAT3. Staining with the antibody for b-
tubulin was used to control sample loading on SDS-PAGEs. Scale bar
10 mm.
doi:10.1371/journal.pone.0049920.g005
Figure 6. CCHCR1 isoform 3 overexpressing cells Iso3Non-risk
and Iso3Risk multiply faster than other stable cell lines. (A) Cell
proliferation was determined by counting the cell numbers with an
automated cell counter (Scepter) during growth periods of 24 or 48 h.
Iso1Non-risk (Iso1N) cells show similar proliferation as wild type (wt,
HEK293) and vector-control (Vector) cells. The greatest difference is
seen between the Iso1Non-risk and isoform 3-expressing cell lines
(Iso3N, Iso3R) (P,0.003) after 24 h, the latter proliferating significantly
faster. (B) Cell cycle is similar in all CCHCR1 cell lines shown by
percentage values. Higher sub-apoptotic population (apop) in Iso3Risk
(Iso3R) cells, however, indicates failure in cell cycle. Cell cycle
progression was determined by treating the cells with 0.3 mM
nocodazole (Noc) or DMSO-control over night, after which the medium
was changed and the cells harvested and fixed at different time points
(0 and 10 h shown). DNA was stained with propidium iodine for FACS
analysis and the proportion of cells in each of the cell cycle stages (G1,
S, G2/M) identified by using the relative DNA content. Asterisks show
significant P-values calculated with values from the vector-control cell
line and the representative cell line (*,0.05.**,0.01).
doi:10.1371/journal.pone.0049920.g006
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in CCHCR1 overexpressing cell lines suggests a role in cell
division and cytokinesis. In skin sections the IEM reveals
CCHCR1 expression also in the proximity of cell membrane
and desmosomes. This may be related to the role of desmosomes
in skin; during epidermal differentiation desmosomes replace
centrosomes as organizators and regulators of microtubulus
cytoskeleton [39].
CCHCR1 regulates cytoskeletal organization
The stably transfected cells overexpressing CCHCR1 show
isoform- and haplotype-specific morphological changes in cell size
and shape, suggesting abnormalities in the organization of
cytoskeleton. The centrosome regulates the organization of
microtubules and through its influence on the cytoskeleton it
affects cell shape and size [21]. Our previous microarray
expression data from transgenic CCHCR1 mice supported a role
in cytoskeleton organization [11]. Here, we demonstrate that
CCHCR1 affects the arrangement and expression of actin,
vimentin, and cytokeratins; Iso3Risk cells show aberrant actin
and vimentin skeleton organization and downregulation of
vimentin and cytokeratins. In psoriatic skin, the expression levels
and patterns of various cytokeratins are dramatically altered and
the amount of vimentin mRNA is reduced [40,41]. Interestingly,
vimentin is involved in the cell proliferation and maintenance of
cell shape [42,43,44], which are biological processes affected also
by CCHCR1. Nocodazole is an agent that disturbs the formation
of microtubule filaments and by this action suggested to alter actin
cytoskeleton [45]. In stable CCHCR1 cell lines, the effect on actin
cytoskeleton is the most obvious in cells treated with nocodazole.
Especially in isoform 3-expressing cells, in addition to filaments,
actin forms clusters or individual spot-like structures resembling
podosomes or invadopodia, which are actin-containing structures
involved in cell migration and invasion. Structures of this type are
referred to as invadopodia when they are found in cancer cells and
as podosomes when found in normal cells. As the formation of
podosomes is suggested to be microtubule dependent [31], the
formation of the structures in CCHCR1-expressing cells in
consequence of microtubule disruption implies invadopodial
nature. Interestingly, several diseases are associated with impair-
ment of podosome formation, most notably Wiskott–Aldrich
syndrome, an X-linked recessive disease with eczema, thrombo-
cytopenia and severe immune deficiencies [31]. Vimentin is
present in the elongated mature invadopodia [46] but similar spot-
like pattern formation after the nocodazole treatment, as with
actin, was not observable with vimentin in cells overexpressing
CCHCR1. Nocodazole also affected CCHCR1 expression and
localization in stable cell lines, suggesting that microtubules
regulate CCHCR1. After the treatment, CCHCR1 is still partly
in association with the centrosomes, but also dispersed into the
cytoplasm as larger aggregates. These aggregates, however, do not
colocalize with the actin-rich spots.
CCHCR1 affects the expression of keratin 17, a hallmark
for psoriasis
The overall expression of cytokeratins decreases most evidently
in Iso3Risk cells and in some extent also in Iso3Non-risk and
Iso1Risk cells. This agrees with our results from experiments with
transgenic mice that overexpress CCHCR1 isoform 3 with the
*WWCC risk-allele, demonstrating keratins as the most strongly
downregulated gene group when compared with non-risk allele
mice [11]. Here we show that in HEK293 cells, the overexpression
of CCHCR1 isoform 1 with the non-risk allele upregulates the
expression of keratin 17 (KRT17), a hallmark and plausible auto-
antigen for psoriasis [32,40,47,48].Correspondingly, the silencing
of CCHCR1 in HEK293 cells, which are homotsygous for the Iso1
allele and are therefore able to express also the isoform 1, reduces
the KRT17 expression. The expression in isoform 3 overexpress-
ing cells is also decreased, which is in contrast to the effects seen in
isoform 1 overexpressing cells. The microarray results from the
skin of transgenic mice [11], however, suggested that KRT17
expression is increased in mice expressing isoform 3 with the risk-
allele (CCHCR1*Iso3WWCC). In human healthy epidermis,
KRT17 is absent but overexpressed in psoriatic lesions
[32,40,49], where it is suggested to promote epithelial prolifera-
tion, modulate immune responses, and to have antiapoptotic
effects [50,51]. The opposite KRT17 expression results obtained
with the overexpressing CCHCR1 cell lines and transgenic mice
might be explained by different expression profiles of keratins
between cultured epithelial cells, like HEK293, and skin. The
environment and cellular interactions are different in cells cultured
in monolayers and cells in intact tissues. In addition to the allele-
specific effects, the expression level of CCHCR1 may affect its
downstream signaling; effects of isoforms 1 and 3 on KRT17
expression may also be dependent on their amount in cells.
Notably, KRT17 is also known to influence cell growth and size
[52] by promoting protein synthesis. Thus, the upregulation of
KRT17 in Iso1Non-risk cells may partially explain the increased
cell size in this cell line.
CCHCR1 regulates EGF-induced STAT3 activation
Our results implicate that CCHCR1 may function in EGFR-
STAT3 signaling pathway. This is based on our observations that
EGF influences CCHCR1 expression [8], and in turn CCHCR1
regulates EGF-induced STAT3 activation. The EGF treatment
increases the CCHCR1 expression both on mRNA and protein
level also in stably transfected CCHCR1 cell lines. EGF is known
to stimulate the expression of several genes through post-
transcriptional mechanisms, genes, such as b-catenin and
thrombospondin-1 [53,54]. We suggest that the EGF-induced
increase in CCHCR1 expression is based both on mRNA and
protein stabilization. Here, we show that CCHCR1 regulates
EGF-induced STAT3 activation in an isoform-specific manner:
STAT3 tyrosine 705 phosphorylation is disturbed in the isoform 3-
expressing cells, whereas the isoform 1 cells activate STAT3
phosphorylation slightly more than the wild type cells. Corre-
spondingly, the silencing of CCHCR1 in HEK293 cells (homo-
tsygous for *Iso1WWCC) decrease the phosphorylation. This is a
relevant observation to the function of CCHCR1 even though the
CCHCR1*Iso3WWCC haplotype associates with decreased STAT3
activation, while epidermal keratinocytes within psoriatic skin are
characterized by activated STAT3, and in transgenic mice the
expression of constitutively active Stat3 leads to a psoriasis like skin
phenotype [20,55]. However, the regulation of STAT3 phosphor-
ylation in skin is probably much more complicated than in cells
cultured in a monolayer, and in psoriatic skin in addition to EGF
numerous other cytokines play a role. Overexpression of
CCHCR1 isoforms does not affect the expression level of STAT3
or its serine 727 phosphorylation or lysine 685 acetylation.
Tyrosine 705 phosphorylation is believed to be crucial for STAT3
activation and nuclear translocation [19,56]. Constitutive activa-
tion of STAT3 in psoriatic skin may result from the persistent
stimulation of EGFR as its multiple ligands are found as increased
levels in psoriatic skin [15,16,20] and as a tyrosine kinase receptor,
EGFR is able to phosphorylate STAT3 directly or indirectly
without Janus kinase (JAK) [17,19,20]. STAT3 regulates various
processes in skin, including cell proliferation, differentiation, and
apoptosis. The regulation is mediated through the transcription of
genes such as cyclin-D, MYC, and BCL-2 [19,20]. Interestingly,
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upregulation of KRT17 expression is also mediated by STAT3
[49], suggesting regulation of KRT17 induction in CCHCR1
isoform 1-expressing HEK293 cells through this pathway. STAT3
is also known to control processes without affecting transcription,
for instance it regulates centrosome doubling by modulating c-
tubulin levels [57]. Furthermore, it regulates the depolymerization
of microtubules by interacting with stathmin, a tubulin binding
protein [58].
CCHCR1 isoform 3 affects cell proliferation
Our earlier findings implicated a role for CCHCR1 in
keratinocyte proliferation [10]. Here we show that the overex-
pression of the novel longer CCHCR1 isoform 1 lacks significant
effects on cell proliferation or cell cycle progression in stable
HEK293 cell lines. Isoform 3 overexpressing cells, however,
multiply faster and the Iso3Risk cells also show increased
apoptosis. After nocodazole synchronization the rate of apoptosis
increases even further as the cell cycle progresses, suggesting
failure to proceed from cell cycle check points, which may result
from the cytoskeletal aberrations. We have earlier shown that
overexpression of CCHCR1 isoform 3 affects cell proliferation in
the skin of transgenic mice; the number of proliferative cells was
20% lower in mice with the CCHCR1*WWCC risk allele than in
non-risk allele mice. In stable cell lines a similar trend (14%) is
observable between Iso3Non-risk and -Risk cell lines (P.0.05). A
more significant difference in cell proliferation, however, is
between isoform 3-expressing cell lines and Iso1Non-risk cells;
both the Iso3Non-risk and –Risk cells multiply faster than the
Iso1Non-risk, wild type or vector control cells. The proliferation
results were not validated by the DNA-based CyQUANTH system,
due to differences in the size of the nuclei between the cell lines. In
transgenic mice the various inductions and the expression level of
CCHCR1 may have affected to the proliferation results [11].
There may be also differences in CCHCR1 function between
mouse and human as well as between cell types.
Conclusions
Functions presented here for CCHCR1 in cytoskeleton
organization and cell proliferation are overlapping and mediated
through centrosomes. In addition to the regulation of cell cycle
and cytokinesis, centrosomal proteins can regulate diverse other
microtubule-based processes such as vesicle docking and mito-
chondria transporting [21,59,60]. Centrosomal proteins can be
very dynamic in trafficking between the centrosome-bound and
cytoplasmic pool, interacting with numerous proteins. CCHCR1
also shows localization in various other compartments in the cell;
midbody, cytoplasm, and in the proximity of the cell membrane
and desmosomes. It enhances the synthesis of steroids by
interacting with the mitochondrial steroidogenic acute regulatory
protein (StAR) [8] and here we propose that it may indirectly
induce steroidogenesis as well. CCHCR1 regulates cytoskeleton,
including vimentin that also plays a role in the synthesis of steroids
by modulating the motility of mitochondria and by binding
cholesterol [61,62]. In addition, CCHCR1 interacts with the RNA
polymerase II subunit 3 (RPB3) [63] and controls its localization.
RPB3 regulates the expression and compartmentalization of
vimentin through the action of eukaryotic translation elongator
factor 1 c (eEF1c) [64,65].Therefore,the effect of CCHCR1 on
vimentin organisation could be mediated through its interaction
partner RPB3. The inhibitory effect of CCHCR1 isoform 3 on
tyrosine phophorylation of STAT3 may also arise from cytoskel-
etal alterations caused by CCHCR1. STAT3 is known to interact
with cytoskeletal structures and drugs used in cancer treatment,
such as microtubule stabilizer paclitaxel and microtubule inhibitor
vinorelbine that decrease the tyrosine phosphorylation of STAT3
and thus inhibit the expression of STAT3 target genes [66].
Paclitaxel is also known to decrease the association between
STAT3 and microtubules. Taken together; we suggest that, as a
dynamic centrosomal protein, CCHCR1 is able to interact with
several proteins and modulate multiple cellular processes that are
involved in psoriatic skin. We also show that the N-terminal part of
the isoform 1 affects the function of CCHCR1 both independently
and in combination with the non-risk/risk (*RRGS/WWCC) status.
Most importantly, we show that the SNP (rs3130453) controlling
the translation start site associates with psoriasis, is in high linkage
disequilibrium with the psoriasis risk-haplotype SNP rs130076,
and that CCHCR1has allele-specific consequences on pathways
and functions relevant to the pathogenesis of the disease.
Materials and Methods
Patient material
In genotyping we utilized DNA samples that have been used in
earlier studies. The Swedish and Finnish psoriasis family material
for genotyping was recruited as previously described: the Swedish
blood samples were collected with the help of the Swedish Psoriasis
Association and approved by the Regional Ethics Committee [67],
the Finnish samples were approved by the Ethics Committees of
Helsinki, Turku, Tampere, and Oulu University Central Hospitals
and Central Hospital of Pa¨ija¨t-Ha¨me [68,69]. The skin samples for
expression studies were dermatome biopsies measuring 562 cm,
4–6/1000 inches thick (ZimmerH dermatome, Minneapolis, MN).
Psoriasis patients were sampled from both the lesional and non-
lesional skin (n = 5). Healthy skin (n = 2) was obtained from
reductive mammoplastic or microvascular free flap surgery
patients. The collection of skin samples was approved by the
Ethics Committee of the Hospital District of Helsinki and
Uusimaa and by the Committee of Skin and Allergy Hospital,
Helsinki University Central Hospital. All participants gave written
informed consent for the blood and skin sample collections and the
studies followed the Declaration of Helsinki Guidelines.
SNP genotyping and association analysis
The samples used for the genotyping consisted of trios from 508
psoriasis families in total, including 245 Finnish and 263 Swedish
families. We genotyped the SNPs rs3130453 and rs130076 by
using DNA extracted from the Finnish and Swedish family
samples. Genotyping was done using TaqMan allelic discrimina-
tion assays (C_2452221_10 and C_2452225_10, respectively) with
probes and primers designed and synthesized by the supplier
(Applied Biosystems). Transmission disequilibrium test (TDT) was
performed using HaploView [70]. To correct for multiple testing,
we performed permutation tests (100000 permutations).
Cloning and constructs
Cloning of cDNAs encoding the isoform 3 with the risk or non-
risk haplotype (SNPs rs130065, rs130076, rs130079, rs1576) has
been described previously [3,11]. The cDNA corresponding for
the N-terminal part of the isoform 1 was obtained from HaCaT
RNA by reverse transcription-PCR (RT-PCR) using primers
(Table S2) designed according to the reference sequence
NM_001105564.1. The isoform 1 non-risk and risk constructs
were engineered combining the novel N-terminal part to the
previous isoform 3 non-risk or risk cDNAs using XbaI site and
ligation. All cDNAs were prepared into the pCMV5 and pDsRed-
Monomer-N1 (Clontech) vectors. To prepare short hairpin
shRNA constructs for CCHCR1 silencing complementary oligos
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(Table S2) based on previous experiments [7] were annealed and
cloned into the pRNAT-CMV3.2/Neo vector with a GFP tag
(GenScript) using BamHI and XhoI sites. Oligos were designed with
GenScript program and scrambled sequence was used to prepare
a control construct.
Cell cultures and transfections
HEK293 cells (American Type Culture Collection) were grown
in Dulbecco’s Modified Eagle’s medium (DMEM) supplemented
with 10% fetal calf serum (FCS) and penicillin-streptomycin (P/S).
HaCaT cells [71] were kindly provided by Prof. N.E. Fusenig
(Heidelberg, Germany) and grown in DMEM supplemented with
5% FCS and P/S. Normal Human Epidermal Keratinocytes
(NHEK, PromoCell) were grown in Keratinocyte Growth
Medium 2 (PromoCell) supplemented with 0.06 mM calcium
and P/S. Plasmid transfections were performed with FuGENE
HD reagent (Roche Diagnostics) according to the manufacturers’
instructions. The cover slips or cell culture wells were coated with
Rat Tail Collagen I (Gibco, Invitrogen) when used for immuno-
fluorescent stainings or nocodazole treatment of HEK293 and
NHEK cells.
Generation of stable cell lines and cell treatments
To generate overexpressing cell lines CCHCR1-pDsRed-
constructs or vector were transfected into HEK293 cells using
standard methods. Cells were grown in the DMEM culture
medium containing 400 mg/ml G418 antibiotics (Roche). After
10–14 days of selection resistant colonies were picked and screened
for CCHCR1 expression by quantitative PCR (qPCR) and
fluorescence microscopy. Protein expression of selected clones
was verified by western blotting and immunofluorescence staining
[3,10]. Stable shRNA cell lines were generated in HEK293 cells
using the same transfection and selection protocol as with
overexpressing cell lines. After G418 selection resistant clones
were screened for plasmid integration by fluorescence microscopy
and for CCHCR1 silencing by qPCR. For the treatment with
epidermal growth factor (EGF) subconfluent cells were grown in
the presence of 20 ng/ml or 100 ng/ml EGF (Sigma). After 2, 6,
or 18 h cells were lysed for western blotting or RNA isolation.
Experiments were repeated three times (western blotting) or
included triplicate samples (qPCR). Disruption of microtubulus
network was performed by incubating the HEK293 stable cells
one hour with 1 mM nocodazole at 37uC. The cell cycle was
synchronized by incubating the cells with 0.3 mM nocodazole over
night at 37uC. DMSO was used as a control.
Antibodies
Antibodies in various immunostainings were: mouse monoclo-
nals against actin (A3853, Sigma); b-catenin (#610154, Trans-
duction Laboratories); cis-golgi marker GM130 (#610822, BD
Transduction Laboratories); keratin 17 (2D4-1G9, Sigma); pan-
cytokeratin (sc-58828, Santa Cruz); Stat3 (#9139, Cell Signaling
Technology); P-Stat3 Ser727 (#9136, Cell Signaling Technology);
acetyl-Stat3 Lys685 (#2523, Cell Signaling Technology); a-, b-
and c-tubulins (T5192, T5201, T5326, Sigma), and vimentin
(V6389, Sigma). Rabbit antibodies used in the study were against:
CCHCR1 [3]; P(S33/37/T41)-b-catenin (#9561, Cell Signaling
technology); and P-Stat3 Tyr705 (# 9145, Cell Signaling
Technology). Antibodies produced in goat were against CCHCR1
(sc-66231, Santa Cruz Biotechnology); and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (sc-20357, Santa Cruz
Biotechnology).
Immunofluorescence
For immunofluorescence studies, cells were fixed with methanol
for 5 min at 220uC or with 4% paraformaldehyde-phosphate
buffered saline (PBS) solution for 15 min at room temperature.
After paraformaldehyde fixation cells were permeabilized with
0.1% Triton-X100 -PBS. For colocalization stainings of endoge-
nous CCHCR1, the HEK293 and HaCaT cells were incubated
over night at 4uC with the antibodies against CCHCR1 and c-
tubulin or phospho-b-catenin (only HEK293 cells). Stable cell lines
expressing pDsRed tagged CCHCR1 isoforms were incubated one
hour at room temperature with the antibodies against following
proteins: c- or a-tubulin, b-catenin, P(S33/37/T41)-b-catenin,
vimentin, GM130, KRT17, pan-cytokeratins and vimentin. Actin
was detected using the Alexa Fluor 488 conjugated phallodin
(Invitrogen, Molecular Probes). NHEK cells transfected with
CCHCR1 constructs were stained with rabbit antibodies for
CCHCR1 one hour and mouse antibodies for c-tubulin one hour.
Alexa Fluor 555 and 488 conjugated IgGs (Invitrogen, Molecular
Probes) were used as secondary antibodies. The nuclei were
stained with DAPI and the pictures taken with Zeiss LSM 5 Duo
confocal microscope.
Immunoelectron microscopy
For IEM, transfected cells were fixed for one hour with 4%
paraformaldehyde-PBS solution, immersed in 12% gelatin-PBS
solution, followed by immersion in 2.3 M sucrose-PBS solution.
Skin biopsies were fixed with paraformaldehyde from 6 to 12 h
followed by immersion in sucrose-PBS solution. Samples were
frozen in liquid nitrogen, and thin cryosections were cut with a
Leica Ultracut UCT microtome. After which they were labeled
with antibodies against CCHCR1 followed by incubation with
gold conjugated protein A. Labeling was detected with a Philips
CM100 transmission electron microscope.
RT-PCR and Quantitative real-Time PCR
Tissue samples for RNA isolation were immediately immersed
into RNAlater Solution (Ambion) and stored according to
manufacturer’s instructions. RNA extraction from cell lines was
done with RNeasy Plus Mini kit (Qiagen) and from tissue (skin
dermatome) samples with miRNeasy Mini kit (Qiagen) comple-
mented with DNase treatment (RNase-Free DNase Set, Qiagen)
according to manufacturer’s instructions. Total RNA was reverse
transcribed to cDNA using TaqMan Reverse Transcription
Reagents (Applied Biosystems) or Transcriptor High Fidelity
cDNA Synthesis Kit (Roche Applied Science). The expression of
CCHCR1 transcript variants 1 and 3 in different tissues and cell
lines was studied with RT-PCR from human Multiple Tissue
cDNA and Fetal and Tumor panels (Clontech), HaCaT and
HEK293 cell lines, and normal human epidermal keratinocytes
(NHEK) using variant specific primers (Table S2). PCR products
were analyzed by agarose gel electrophoresis. Primers for
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression
were used to control amplification. CCHCR1 expression was
measured from cell lines and skin biopsies using qPCR (7500 Fast
Real-Time PCR System, Applied Biosystems) either with TaqMan
reagents (TaqMan Universal PCR Master Mix, pre-designed
systems for CCHCR1 #Hs00219401_m1 and GAPDH
#4310884E, Applied Biosystems) or SYBR green reagents (SYBR
Green PCR Master Mix, Applied Biosystems) and CCHCR1
specific primers (Table S2). Pre-designed TaqMan system
(Hs01588578_m17, Applied Biosystems) was used to study the
KRT17 expression. TATA binding protein (TBP) and GAPDH
were used as control genes in quantification [72].
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Western blotting
Cells grown on 6-well plates were homogenized into 300 ml of
Laemmli buffer containing 5% b-mercaptoethanol. A total of
15 ug or 30 ug of protein per sample was analyzed by SDS-PAGE
using 7.5% polyacrylamide gels. Western blot analysis was carried
out by standard protocols using the following primary antibodies
against: actin, CCHCR1, KRT17, pan-cytokeratin Stat3, P-Stat3
Tyr705, P-Stat3 Ser727, acetyl-Stat3 Lys685, and vimentin.
Immunostaining with antibodies against b-tubulin or GAPDH
were used to control loading. After incubation with the
appropriate horseradish peroxidase-conjugated secondary anti-
bodies (Sigma), signals were detected with an enhanced-chemilu-
minescence (ECL) substrate (Amersham Biosciences/GE Health-
care).
Flow cytometry and cell proliferation measurements
To study cell cycle in stable CCHCR1 cell lines by flow
cytometry, cells grown as duplicates on 12-well plates were
trypsinized, pooled, and fixed in ice cold 70% ethanol and stored
at 220uC over night. To determine cell cycle progression after
synchronization, the cells were synchronized into G2/M-phase by
treating the cells with 0.3 mM nocodazole over night (DMSO was
used as a control). The media were changed and the cells collected
and fixed at different time points. The cells were divided into
duplicate samples on 96-well plates and then washed two times
with PBS. After treating the cells with 0.1 mg/ml ribonuclease A
in PBS for 30 min at 37uC, the nuclei were stained with
0.025 mg/ml propidium iodide (PI) solution (P1304MP, Invitro-
gen) in 2% FCS-PBS. FACSarray (Becton Dickinson) was used for
the detection of PI staining and cell cycle analysis. The experiment
was repeated three times. The cell proliferation of stable
CCHCR1 cell lines was determined with the automated cell
counter (Scepter, Millipore). Cells were seeded at the density of
2.56105 on 12-well plates and after 24 and 48 h of incubation at
37uC they were trypsinized and counted. The experiment was
repeated six times. We also utilized the CyQUANTH Cell
Proliferation assay (Invitrogen) to study cell proliferation. Briefly,
the cells were seeded at the density of 0.56104 or 1.06104 on 96-
well plates coated with Rat Tail Collagen I (Gibco, Invitrogen) and
allowed to grow at 37uC for 0–48 h. The medium was discarded at
specific time points and the cells frozen and stored in 280uC for
analysis. The staining was performed according to manufacturer’s
protocol and the fluorescence measured with Victor Multilabel
reader (Wallac, excitation: 480 nm, emission: 530 nm). The size of
the nuclei in the stable cell lines was measured from the confocal
microscope pictures in which the nuclei were stained with DAPI,
using the Zeiss LSM Image Browser 4.2 (Carl Zeiss MicroImaging
GmbH).
Statistical analysis
All statistical analyses were made using Microsoft Office Excel.
Statistical comparisons between data sets were made with
Student’s t-test and P,0.05 was considered significant.
Supporting Information
Figure S1 Establishment of stable cell lines overex-
pressing CCHCR1. CCHCR1 expression in stable cell lines
was verified by (A) immunofluorescence staining and (B) Western
blotting. (A) As shown by immunofluorescence, all DsRed-tagged
CCHCR1 isoforms (red) are recognized by the CCHCR1
antibody (green). In contrast to the C-terminally tagged DsRed-
CCHCR1, the N-terminally targeted CCHCR1 antibody detects
endogenous protein also at the cell-cell borders (white arrows).
DAPI stained nuclei are shown in blue. Scale bar 10 mm. (B)
Western blotting demonstrates CCHCR1 expression in all four
cell lines: Iso1Non-risk (Iso1N), Iso1Risk (Iso1R), Iso3Non-risk
(Iso1N) and Iso3Risk (Iso1R) and, in reducing conditions, the
antibody against CCHCR1 detects polypeptides of expected size.
Interestingly, the expression of Iso3Non-risk isoform is higher than
other CCHCR1 isoforms, although the CCHCR1 RNA expres-
sion in Iso3Non-risk cells is rather similar to other cell lines (a
longer exposure shown in the right-side panel). The cells were
grown also in the presence of EGF, which increases the protein
level. (C) The IEM studies of stably transected HEK293 cell lines
demonstrate that CCHCR1 is present at the pericentrosomal
region at about 200–1000 nm distance apart from the centrioles.
Scale bar 500 nm (D) Stable shRNA-expressing cell lines were
verified by qPCR. The silencing of CCHCR1 in HEK293 cells
(shRNA) downregulates its expression by 50–60%. Scrambled
sequence was used to generate control cell line (Scr).
(TIF)
Figure S2 Expression pattern of CCHCR1 in transfected
cells. (A) CCHCR1 (red) colocalizes with c-tubulin (green) also in
transiently transfected primary keratinocytes. (B) The Iso3Risk
shows stronger perinuclear staining than the other constructs.
Immunofluorescence staining of transfected cells with CCHCR1
antibody suggests that the cytoplasmic granules are smaller when
formed by the Iso3Non-risk or the Iso1 constructs than by the
Iso3Risk construct. (C) IEM of transfected COS-7 supports the
observation; the gold label in the cytoplasm is observed as clusters
that are larger in the Iso3Risk than Iso3Non-risk cells. (D) Cis-
golgi marker GM130 (green) surrounds and has partial colocaliza-
tion with the centrosomal CCHCR1 (red) in stably transfected
CCHCR1 cell lines (here shown Iso1Non-risk). DAPI stained
nuclei are shown in blue. Scale bar 10 mm.
(TIF)
Figure S3 Localization of endogenous CCHCR1. Immu-
nofluorescence staining shows that the endogenous CCHCR1
localizes at the centrosome in (A) HEK293 and (B) HaCaT cells.
Cells were stained with CCHCR1 (green) and c-tubulin (red)
antibodies. The last picture shows magnification of the centroso-
mal region, marked in the merge channel pictures. DAPI stained
nuclei are shown in blue. The scale bars are 10 mm and 2 mm (the
magnified picture).
(TIF)
Figure S4 Morphological and cytoskeletal differences in
stably transfected CCHCR1 cell lines. Comparison of all
four CCHCR1 and control cell lines stained with antibodies
against (A) a-tubulin and (B) vimentin. The stainings (green) reveal
alterations in the cell morphology and cytoskeleton of cells
expressing different CCHCR1 isoforms (red). (A) The a-tubulin
staining pattern is otherwise unchanged in CCHCR1 overex-
pressing cells. Especially the Iso1Non-risk cell line exhibits
multinuclei (indicated with an arrow). (C) The average size of
the nuclei is significantly smaller in the isoform 3-expressing cells
when compared to the vector-control cell line and even more
significant when compared to Iso1Non-risk cells. Asterisks show
significant P-values calculated with values from the vector-control
cell line and the representative cell line
(*,0.05.**,0.01.***,0.001). (B) Vimentin expression and
organization is disturbed in both Iso3Non-risk and -risk cell lines
as shown by immunofluorescence. (D) Immunoblotting with
vimentin antibody, however, lacks evidence for major changes in
expression between stable CCHCR1 cell lines. A magnification of
the centrosomal region from Iso1Non-risk cells with the vimentin
staining (B) shows that the CCHCR1 is not surrounded by a
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vimentin cage, which is typical for aggresomes. DAPI stained
nuclei are shown in blue. Scale bar 10 mm.
(TIF)
Figure S5 Microtubule disturption shows altered orga-
nization of the actin cytoskeleton in CCHCR1 Iso3Risk
overexpressing cells. (A) Phalloidine staining shows that
isoform 3-expressing cells exhibit more pseudopodia with actin
rich tips, indicated by an arrowhead (Iso3Non-risk, Ctrl). (B) The
most obvious change in actin organization is observed in the
Iso3Risk cells, after treatment with nocodazole (Noc); actin forms
punctate staining resembling podosome-like structures, indicated
by an arrowhead (Iso3Risk, Noc). (C) The localization of
CCHCR1 is partially changed after the disruption of microtubule
network with nozodazole. DAPI stained nuclei are shown in blue.
Scale bar 10 mm.
(TIF)
Figure S6 CCHCR1 affects the expression of cytoker-
atins. Immunofluorescence staining of (A) pan-cytokeratin and
(B) keratin 17 in all four CCHCR1 overexpressing cell lines and
vector control cells. (A) The overall expression of cytokeratins is
reduced especially in the Iso3Risk-expressing cells. (B) Iso1Non-
risk-expressing cells show an increase in the expression of keratin
17. DAPI stained nuclei are shown in blue. Scale bar 10 mm.
(TIF)
Figure S7 Overexpression of CCHCR1 in stable cell
lines does not affect STAT3 serine 727 phosphorylation
or lysine 685 acetylation. Staining with an antibody for b-
tubulin or GAPDH was used to control sample loading on SDS-
PAGEs.
(TIF)
Table S1 Expression of CCHCR1 transcript variants 1
and 3 in various human tissues and cell lines. Transcripts
did not show major differences in their expression; both were
detectable in all tissues and cells studied. Here shown band
intensities of RT-PCR samples run on agarose gel: from low (+) to
high, (+++++).
(XLS)
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